<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16</volume><submitter>Xu W</submitter><pubmed_abstract>&lt;h4>Aim&lt;/h4>To explore clinical features and prognosis of hepatocellular carcinoma (HCC) in hepatitis B virus surface antigen (HBsAg)-serocleared patients and identify risk factors associated with postoperative recurrence after curative hepatectomy.&lt;h4>Methods&lt;/h4>Patients who had undergone initial hepatectomy for HCC from January 2010 through December 2022. Clinicopathological data were compared between HBsAg-seropositive and HBsAg-serocleared patients. Furthermore, risk factors associated with early and late postoperative HCC recurrence (early and late recurrences (ER and LR), respectively) were analyzed for HBsAg-serocleared HCC patients treated by curative hepatectomy.&lt;h4>Results&lt;/h4>A total of 2184 consecutive patients undergoing initial hepatectomy for HCC were enrolled, including 33</pubmed_abstract><journal>Therapeutic advances in medical oncology</journal><pagination>17588359241289202</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11526261</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Hepatocellular carcinoma in HBsAg seroclearance: clinical features, recurrence, and prognosis following curative hepatectomy.</pubmed_title><pmcid>PMC11526261</pmcid><pubmed_authors>Yin X</pubmed_authors><pubmed_authors>Li B</pubmed_authors><pubmed_authors>Xu W</pubmed_authors><pubmed_authors>Gong H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Hepatocellular carcinoma in HBsAg seroclearance: clinical features, recurrence, and prognosis following curative hepatectomy.</name><description>&lt;h4>Aim&lt;/h4>To explore clinical features and prognosis of hepatocellular carcinoma (HCC) in hepatitis B virus surface antigen (HBsAg)-serocleared patients and identify risk factors associated with postoperative recurrence after curative hepatectomy.&lt;h4>Methods&lt;/h4>Patients who had undergone initial hepatectomy for HCC from January 2010 through December 2022. Clinicopathological data were compared between HBsAg-seropositive and HBsAg-serocleared patients. Furthermore, risk factors associated with early and late postoperative HCC recurrence (early and late recurrences (ER and LR), respectively) were analyzed for HBsAg-serocleared HCC patients treated by curative hepatectomy.&lt;h4>Results&lt;/h4>A total of 2184 consecutive patients undergoing initial hepatectomy for HCC were enrolled, including 33</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024</publication><modification>2025-04-26T17:02:26.719Z</modification><creation>2025-04-06T15:21:55.639Z</creation></dates><accession>S-EPMC11526261</accession><cross_references><pubmed>39483138</pubmed><doi>10.1177/17588359241289202</doi></cross_references></HashMap>